,
,
, « Projection de l'incidence et de la mortalité par cancer en France métropolitaine en, Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil, 2017.
,
, de-la-mortalite-par-cancer-en-France-metropolitaine-en-2017
,
,
, « Cancer | LEEM -Les entreprises du médicament
,
, « Le cancer en chiffres | Fondation ARC pour la recherche sur le cancer
, Disponible sur: /le-cancer-en-chiffres
, Prévention du cancer
,
Réseau français des registres des cancers (Francim)., « Environnement socioéconomique et incidence des cancers en France, Bull Epidémiol Hebd, issue.4, pp.68-77, 2017. ,
« The Hallmarks of Cancer, vol.100, pp.57-70, 2000. ,
« Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-998, 2002. ,
, The Eukaryotic Cell Cycle, 2000.
, « Cell Cycle Regulation by Checkpoints », vol.1170, pp.29-40, 2014.
« Cyclin D activates the Rb tumor suppressor by mono-phosphorylation, vol.3, 2014. ,
« BRCA mutations in the manifestation and treatment of ovarian cancer, Oncotarget, vol.8, pp.97657-97670, 2017. ,
, DNA Repair Deficiency, and Ovarian Aging, vol.93, issue.3, 2015.
« Regulation of the p53 transcriptional activity, J. Cell. Biochem, vol.97, issue.3, pp.448-458, 2006. ,
, New England Journal of Medicine, vol.356, issue.1, pp.79-81, 2007.
« Ras signaling in aging and metabolic regulation, Nutr Healthy Aging, vol.4, pp.195-205 ,
« Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer, J Natl Cancer Inst, vol.99, issue.8, pp.628-638, 2007. ,
, « Les cancers en France en 2016 -L'essentiel des faits et chiffres -Ref : ETKAFRSYN16 | Institut National Du Cancer
,
,
« Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals, BMJ, vol.359, issue.13, p.4530, 2009. ,
,
,
,
,
Medecine personnalisee medecine du futur ,
,
, Médecine personnalisée et thérapies ciblées pour traiter les pathologies graves
,
, « Les thérapies ciblées dans le traitement du cancer, état des lieux en 2015 et enjeux, 2016.
« VEGF-receptor signal transduction », Trends in Biochemical Sciences, vol.28, issue.9, pp.488-494, 2003. ,
, Immunothérapie : la révolution attendue contre le cancer », Institut Curie
,
A caring culture, Nature, vol.504, pp.4-5 ,
mode d'action -Thérapies ciblées et immunothérapie spécifique | Institut National Du Cancer ,
, The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma, vol.37, pp.764-782, 2015.
« Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?, Cell Biosci, vol.8, 2018. ,
, Cancer Immunotherapy », Science, vol.342, pp.1432-1433
, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, vol.376, pp.836-847, 2017.
Cancer vaccines on the move », Nature Reviews Clinical Oncology, 2017. ,
« Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat Rev Immunol, vol.18, issue.3, pp.168-182, 2018. ,
, Fournier-Majoie Foundation, « Les biomarqueurs du cancer
,
« Protein biomarker discovery and validation: the long and uncertain path to clinical utility », Nature Biotechnology, vol.24, issue.8, pp.971-983, 2006. ,
Tyler) Yin, « Fundamentals of Pharmacogenetics in Personalized, Precision Medicine », Clinics in Laboratory Medicine, vol.36, issue.3, pp.447-459, 2016. ,
, Agence nationale de sécurité du médicament et des produits de santé
, Role of Biomarkers in Personalized Medicine, pp.91-97, 2015.
« Phases of Biomarker Development for Early Detection of Cancer, J Natl Cancer Inst, vol.93, pp.1054-1061, 2001. ,
« From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development, Cancer Discov, vol.3, issue.2, pp.148-157, 2013. ,
, J Natl Cancer Inst, vol.107, issue.8, 2015.
, « Liste des tests de génétique somatique réalisés par les plateformes de génétique moléculaire des cancers
, « Plateformes hospitalières de génétique moléculaire des cancers : faits marquants et synthèse d'activité 2013 -Ref : BILPTFMOL14 | Institut National Du Cancer
,
« Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol Oncol, vol.8, issue.6, pp.1095-1111, 2014. ,
, Nature, vol.501, pp.328-337, 2013.
« Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity, Cell Rep, vol.6, issue.3, pp.514-527, 2014. ,
« Role of ABC transporters in cancer chemotherapy, Chin J Cancer, vol.31, issue.2, pp.51-57 ,
« Targeting multidrug resistance in cancer », Nature Reviews Drug Discovery, vol.5, issue.3, pp.219-234, 2006. ,
« Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011. ,
, Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth », vol.7, pp.2443-2458, 2015.
« The tumor microenvironment at a glance, J Cell Sci, vol.125, issue.23, pp.5591-5596 ,
« Tumor-Associated Macrophages, Inflammation and Pathogenesis of Hepatocellular Carcinoma, Journal of Molecular and Genetic Medicine, vol.08, p.3, 2014. ,
innate immunity and cancer: balance, tolerance, and diversity, Current Opinion in Immunology, vol.22, issue.2, pp.231-237 ,
« Role of tumor-associated macrophages in the progression of hepatocellular carcinoma, Surg Today, vol.42, issue.1, pp.1-7, 2011. ,
« Cancer drug resistance: an evolving paradigm », Nature Reviews Cancer, vol.13, issue.10, p.714, 2013. ,
« Tumour heterogeneity and resistance to cancer therapies », Nature Reviews Clinical Oncology, 2017. ,
La recherche fondamentale | Inserm -La science pour la santé ,
, Recherche fondamentale > Définition | Fondation Synergie Lyon Cancer
,
« The Valley of Death in anticancer drug development: a re-assessment », Trends Pharmacol Sci, vol.33, issue.4, pp.173-180, 2012. ,
Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development, Stem Cells Transl Med, vol.6, pp.2115-2125, 2017. ,
« Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays, Oncotarget, vol.8, issue.5, p.8854, 2017. ,
, « Le développement préclinique ou la première évaluation | LEEM -Les entreprises du médicament
,
, Thoughts on limitations of animal models, vol.14, pp.81-83, 2008.
« Why animal studies are often poor predictors of human reactions to exposure, J R Soc Med, vol.102, issue.3, pp.120-122, 2009. ,
, « Failures in Phase III: Causes and Consequences », vol.21, pp.4552-4560, 2015.
, Nanomedicine approaches to improve cancer immunotherapy, vol.9, 2017.
« Liposomes for Use in Gene Delivery, J Drug Deliv, vol.2011, 2011. ,
« Triggering bilayer to inverted-hexagonal nanostructure formation by thiol-ene click chemistry on cationic lipids: consequences on gene transfection, Soft Matter, vol.12, pp.4516-4520, 2016. ,
« Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex vivo and Distribution in vivo, ACS Nano, vol.9, issue.9, pp.9217-9227, 2015. ,
« Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer, vol.17, issue.1, pp.20-37, 2017. ,
« Gene therapy and DNA delivery systems, International Journal of Pharmaceutics, vol.459, issue.1, pp.70-83, 2014. ,
, Genomics, Biogenesis, Mechanism, and Function, vol.116, pp.281-297, 2004.
« microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges, Front. Endocrinol, vol.6, 2016. ,
« Clinical relevance of circulating cell-free microRNAs in cancer, Nat Rev Clin Oncol, vol.11, issue.3, pp.145-156, 2014. ,
, MicroRNAs in body fluids-the mix of hormones and biomarkers, vol.8, p.467
« MicroRNA therapeutics: towards a new era for the management of cancer and other diseases », Nature Reviews Drug Discovery, vol.16, issue.3, pp.203-222, 2017. ,
« Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34 », Cancer Res, vol.70, pp.5923-5930 ,
« The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 », Nature Medicine, vol.17, issue.2, pp.211-215, 2011. ,
« Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice, Molecular Therapy, vol.19, issue.6, pp.1116-1122, 2011. ,
« Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer, Cancer Cell, vol.23, issue.2, pp.186-199, 2013. ,
« Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment, Cancer Discov, vol.3, issue.11, pp.1302-1315, 2013. ,
« Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression, Oncogene, vol.35, pp.4312-4320, 2016. ,
« A review of the current status of siRNA nanomedicines in the treatment of cancer, Biomaterials, vol.34, pp.6429-6443, 2013. ,
, A potential cancer therapy? », vol.98, pp.159-169, 2016.
« Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo, Journal of Controlled Release, vol.220, pp.631-641, 2015. ,
, Advances in siRNA delivery in cancer therapy », Artificial Cells, vol.46, pp.274-283, 2018.
, « Gene Therapy Used in Cancer Treatment », Biomedicines, vol.2, issue.2, pp.149-162, 2014.
, Identification and characterization of a new member of the TNF family that induces apoptosis, vol.3, pp.673-682, 1995.
« Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy, ACS Nano, vol.12, issue.2, pp.912-931, 2018. ,
, « Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK, vol.89, pp.845-856, 2017.
« DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells, Mol Oncol, vol.11, pp.1733-1751, 2017. ,
« The TRAIL apoptotic pathway in cancer onset, progression and therapy », Nature Reviews Cancer, vol.8, issue.10, pp.782-798, 2008. ,
« Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival, Clin Cancer Res, vol.16, issue.8, pp.2363-2374 ,
« TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models, International Journal of Cancer, vol.139, pp.2802-2811, 2016. ,
« Therapy of primary and metastatic liver cancer by human iPS cellderived myeloid cells producing interferon-? », Journal of Hepato-Biliary-Pancreatic Sciences, vol.24, issue.2, pp.109-119, 2017. ,
« Cancer immunotherapy using CAR-T cells: from the research bench to the assembly line, Biotechnol J, vol.13, issue.2, 2018. ,
« Manufacture of CAR-T cells in the body », Nature Biotechnology, vol.35, issue.6, pp.520-521, 2017. ,
, The International SNP Map Working Group, « A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, vol.409, pp.928-933, 2001.
« DNA sequencing with chain-terminating inhibitors », Proc Natl Acad Sci U S A, vol.74, pp.5463-5467 ,
, Impact du séquençage d'ADN à haut débit sur la surveillance des épidémies de bactéries multi-résistantes aux antibiotiques, vol.354, 2017.
, Textbook of Personalized Medicine, pp.99-148, 2015.
Tyler) Yin, « Fundamentals of Pharmacogenetics in Personalized, Precision Medicine », juill, 2016. ,
, « Recherche d'un déficit en dihydropyrimidine déshydrogénase visant à prévenir certaines toxicités sévères associées aux traitements
« Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions, Journal of Pharmaceutical Sciences, 2017. ,
, Textbook of Personalized Medicine, pp.149-158, 2015.
, Endopredict et Prosigna dans le cancer du sein de stade précoce, « Haute Autorité de Santé -Avis n° 2019.0003/AC/SEAP du 9 janvier 2019 du collège de la HAS relatif à l'inscription sur la LAP mentionnée à l'article L. 162-1-7 du CSS des signatures génomiques Oncotype Dx
« Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention, Oncotarget, vol.5, pp.4603-4650, 2014. ,
« HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma, Clin Cancer Res, vol.21, issue.3, pp.526-533, 2015. ,
, Triple negative breast cancer: the kiss of death, vol.8, pp.46652-46662, 2017.
« Atezolizumab for the treatment of triple-negative breast cancer, Expert Opinion on Investigational Drugs, vol.28, issue.1, pp.1-5, 2019. ,
« Immunotherapy in triple-negative breast cancer, Med Oncol, vol.35, issue.1, p.13, 2017. ,
« Breast Cancer Immunotherapy: Facts and Hopes, Clin Cancer Res, vol.24, issue.3, pp.511-520, 2018. ,
ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development, J Clin Oncol, vol.33, pp.1397-1406, 2015. ,
, Cancer Susceptibility and the Functions of BRCA1 and BRCA2, vol.108, pp.171-182, 2002.
, Therapeutic Applications of PARP Inhibitors: Anticancer Therapy and Beyond, vol.34, 2013.
« The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies, Cancer, vol.123, issue.11, pp.1912-1924, 2017. ,
« Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, Nat Commun, vol.7, p.13665, 2016. ,
« EGFR signaling in colorectal cancer: a clinical perspective, Gastrointestinal Cancer: Targets and Therapy, pp.19-2015 ,
Based Detection Methods for Single-Nucleotide Polymorphism or Mutation: Real-Time PCR and Its Substantial Contribution Toward Technological Refinement, Advances in Clinical Chemistry, vol.80, pp.45-72, 2017. ,
, Handbook of Pharmaceutical Biotechnology, pp.1463-1489, 2006.
, Biomarkers in Cancer Detection, vol.34, issue.1, 2017.
, Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis », vol.40, pp.172-186, 2019.
, « Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition », Science, vol.339, pp.580-584, 2013.
« Circulating tumor cell isolation, culture, and downstream molecular analysis, Biotechnology Advances, vol.36, issue.4, pp.1063-1078, 2018. ,
« Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility, Science, vol.345, pp.216-220, 2014. ,
« Les acides nucléiques du plasma sanguin chez l'homme, C. R. Seances Soc. Biol. Fil, vol.142, pp.241-243, 1948. ,
, des résultats et des projets... », Institut Curie
« Circulating tumor-derived DNA is shorter than somatic DNA in plasma, Proceedings of the National Academy of Sciences of the United States of America, vol.112, pp.3178-3179, 2015. ,
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer, Oncotarget, vol.7, pp.48832-48841, 2016. ,
« The Origin and Mechanism of Circulating DNA », Annals of the New York Academy of Sciences, vol.906, issue.1, pp.161-168, 2000. ,
« Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing, Res Rep Urol, vol.4, pp.33-40 ,
« Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma, Nat Commun, vol.6, p.8839, 2015. ,
« Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas, Sci Transl Med, vol.7, pp.293-104, 2015. ,
« Toward liquid biopsies in cancer treatment: application of circulating tumor DNA, APMIS, vol.0, p.0 ,
, Quel avenir pour l'ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques », vol.103, pp.55-65, 2016.
, Les microRNA comme biomarqueurs : quelles perspectives ? », Comptes Rendus Biologies
Genomic Instability and Cancer, Int J Mol Sci, vol.15, issue.8, pp.14475-14491, 2014. ,
, Potential Biomarkers for Cancer, vol.12, issue.3, pp.2055-2063, 2011.
« Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis, Cancer Cell, vol.26, issue.5, pp.707-721, 2014. ,
Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, vol.9, issue.6, pp.654-659, 2007. ,
, Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function, vol.13, pp.17-24, 2015.
Biogenesis and secretion of exosomes, Current Opinion in Cell Biology, vol.29, pp.116-125, 2014. ,
, Exosome and its roles in cardiovascular diseases, vol.20, pp.337-348, 2015.
, Multivesicular Endosome Biogenesis in the Absence of ESCRTs », Traffic, vol.10, pp.925-937, 2009.
Diagnostic and Prognostic Potential of Extracellular Vesicles in Peripheral Blood », Clinical Therapeutics, vol.36, issue.6, pp.830-846, 2014. ,
« Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy », Exp Mol Med, vol.49, issue.1, p.285, 2017. ,
Novel Biomarkers for Clinical Diagnosis, ScientificWorldJournal, vol.2015, 2015. ,
, High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients », vol.4, 2009.
« Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers, Nat Cell Biol, vol.10, pp.1470-1476, 2008. ,
« Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma, Cancer, vol.119, issue.6, pp.1159-1167, 2013. ,
, , 2014.
,
, Clinical Trials Market Size Worth $65.2 Billion By 2025 | CAGR: 5.7% »
,
« Key cost drivers of pharmaceutical clinical trials in the United States, Clinical Trials, vol.13, issue.2, pp.117-126, 2016. ,
,
, Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results, vol.176, pp.1826-1833, 2016.
« Failure modes in anticancer drug discovery and development, Cancer Drug Design and Discovery, pp.424-435, 2008. ,
« Why Do Phase III Clinical Trials in Oncology Fail so Often?, J Natl Cancer Inst, vol.104, issue.8, pp.568-569, 2012. ,
« Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer, J Natl Cancer Inst, vol.104, issue.8, pp.590-598, 2012. ,
, Economics of New Oncology Drug Development », JCO, vol.25, pp.209-216, 2007.
« Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review, Cancer Treatment Reviews, vol.52, pp.12-21, 2017. ,
, Top Clinical Trial Failures of 2016 | The Lists, vol.13
, « Future Clinical Trials: Genetically Driven Trials, vol.26, issue.4, pp.791-797, 2017.
, Impact of biomarker usage on oncology drug development, vol.38, pp.62-67, 2013.
« Believe it or not: how much can we rely on published data on potential drug targets? », Nature Reviews Drug Discovery, vol.10, issue.9, p.712, 2011. ,
« Drug development: Raise standards for preclinical cancer research », Nature, 28-mars-2012 ,
,
« Development of Personalized Medicine, Textbook of Personalized Medicine, pp.589-654, 2015. ,
« Precision Oncology: A New Era of Cancer Clinical Trials, Cancer Lett, vol.387, pp.121-126, 2017. ,
« Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 », New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001. ,
« Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial », Br J Cancer, vol.111, issue.1, pp.17-24, 2014. ,
« Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, openlabel, proof-of-concept, randomised, Lancet Oncol, vol.16, issue.13, pp.1324-1334, 2015. ,
, Clinical trial designs incorporating predictive biomarkers, vol.43, pp.74-82, 2016.
France médecine génomique, 2025. ,
,
,
,
Deux plateformes de séquençage très haut débit pour la médecine génomique ,
« Limits to Personalized Cancer Medicine, New England Journal of Medicine, vol.375, pp.1289-1294, 2016. ,
« Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar, MAbs, vol.9, issue.4, pp.704-714, 2017. ,
« Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients, J Transl Med, vol.11, p.307, 2013. ,
, « Dépistage et détection précoce -Professionnels de santé | Institut National Du Cancer
« HPV vaccines -A review of the first decade, Gynecologic Oncology, vol.146, issue.1, pp.196-204, 2017. ,
Faculté de médecine Paris Descartes -Ethique et cancer : la médecine personnalisée ,
,
,
Cancer Genome Atlas Home Page », The Cancer Genome Atlas -National Cancer Institute ,
,
« The causes and consequences of genetic heterogeneity in cancer evolution, Nature, vol.501, 2013. ,
, Nature, vol.501, 2013.
, Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs, vol.87, pp.272-277, 2010.
« Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis, JAMA Oncol, vol.2, issue.11, pp.1452-1459, 2016. ,
, Current advances in T-cell-based cancer immunotherapy, vol.6, pp.1265-1278, 2014.
« The future of clinical research in oncology: where are we heading to?, Chinese Clinical Oncology, vol.2, issue.1, 2013. ,
« The ethics of personalized medicine, Personalized Medicine Universe, vol.3, pp.42-45, 2014. ,